The tweet was deleted by the author.
But we saved everything 🙂.
Tempus achieved a significant development with the U.S. Food and Drug Administration granting approval for a tumor-only indication of xT CDx, according to Eric Lefkofsky.
This regulatory milestone allows use of Tempus’ genomic profiling solution in instances where blood or saliva samples are not feasible. The decision aims to broaden access to advanced genomic profiling, ensuring that more patients can benefit from comprehensive cancer diagnostics, even with limited sample availability.